Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

Bibliographic Details
Main Authors: Ario Takeuchi, Masaki Shiota
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:IJU Case Reports
Online Access:https://doi.org/10.1002/iju5.12181
id doaj-2f4d2875a6764ffb86110d5ae582190f
record_format Article
spelling doaj-2f4d2875a6764ffb86110d5ae582190f2020-11-25T03:18:51ZengWileyIJU Case Reports2577-171X2020-09-013517918010.1002/iju5.12181Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinomaArio Takeuchi0Masaki Shiota1Department of Urology Graduate School of Medical Sciences Kyushu University Fukuoka JapanDepartment of Urology Graduate School of Medical Sciences Kyushu University Fukuoka Japanhttps://doi.org/10.1002/iju5.12181
collection DOAJ
language English
format Article
sources DOAJ
author Ario Takeuchi
Masaki Shiota
spellingShingle Ario Takeuchi
Masaki Shiota
Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
IJU Case Reports
author_facet Ario Takeuchi
Masaki Shiota
author_sort Ario Takeuchi
title Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_short Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_full Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_fullStr Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_full_unstemmed Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
title_sort editorial comment to resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
publisher Wiley
series IJU Case Reports
issn 2577-171X
publishDate 2020-09-01
url https://doi.org/10.1002/iju5.12181
work_keys_str_mv AT ariotakeuchi editorialcommenttoresumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
AT masakishiota editorialcommenttoresumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma
_version_ 1724625448821850112

Similar Items